Improving treatment outcome assessment in a mouse tuberculosis model
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improving treatment outcome assessment in a mouse tuberculosis model
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1038/s41598-018-24067-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious DiseasesIn VivoPharmacology Workshop for TB Drug Development
- (2016) Eric Nuermberger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)
- (2016) Patrick P. J. Phillips et al. BMC Medicine
- Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis
- (2015) Rokeya Tasneen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Moxifloxacin-Containing Regimens in Pathologically Distinct Murine Tuberculosis Models
- (2015) Si-Yang Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Nonclinical Models for Antituberculosis Drug Development: A Landscape Analysis
- (2015) Tawanda Gumbo et al. JOURNAL OF INFECTIOUS DISEASES
- PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice
- (2014) Noton K. Dutta et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
- (2014) Stephen H. Gillespie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of Moxifloxacin or Levofloxacin in Second-Line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis
- (2013) Zahoor Ahmad et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model
- (2013) Jurriaan E. M. de Steenwinkel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse
- (2013) Patrick P. J. Phillips et al. PLoS One
- Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
- (2012) Ian M. Rosenthal et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide
- (2012) J. Grosset et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs againstMycobacterium tuberculosis
- (2010) Mary A. De Groote et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig
- (2010) Z. Ahmad et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis
- (2009) D. Almeida et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
- (2009) Marcus B Conde et al. LANCET
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
- (2008) E. Nuermberger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More